Loading quotes...
Forecast
| Buy |
3 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
Acasti Pharma reports significant profit increase in the quarter
Acasti Pharma posted earnings per share of $0.05 in the past quarter, after reporting a loss of -$0.34 per share in the same period last year. For the full year, the loss per share was reduced to -$0.79, compared to -$1.35 the previous year. The figures indicate a marked improvement in the company's financial position. » More on finanzen.net
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -13.84M | 385.04% |
| EBITDA | 0 | 100.00% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €29.36M |
Number of shares | 10.14M |
52-week high/low | €3.09 - €1.70 |
| Dividends | No |
Beta | 1.52 |
P/E ratio | -1.67 |
PEG ratio | 0.01 |
P/B ratio | 0.75 |
P/S ratio | 0.00 |
Company profile
Acasti Pharma Inc. ist ein biopharmazeutisches Unternehmen, das pharmazeutische Produkte für Herz-Kreislauf-Erkrankungen entwickelt und vermarktet. Das Unternehmen prüft strategische Partnerschaften für die klinische Entwicklung von CaPre, einem Omega-3-Phospholipid-Therapeutikum zur Behandlung von Patienten mit Hypertriglyceridämie. Das Unternehmen wurde im Jahr 2002 gegründet und hat seinen Hauptsitz in Laval, Kanada.
| Name | Acasti Pharma |
| CEO | Prashant Kohli |
| Headquarters | Laval,
qc USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 02/07/2012 |
| Employees | 32 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ACST |
Discover assets
Shareholders of Acasti Pharma also invest in the following assets
